Trial Profile
ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions
- Acronyms STANDARD-VTE study
- Sponsors Bristol-Myers Squibb; Pfizer
- 15 May 2021 Status changed to completed, according to Results published in the Circulation Journal
- 15 May 2021 Results of final analysis published in the Circulation Journal
- 19 Oct 2016 Status changed from not yet recruiting to recruiting.